Autolus Therapeutics plc (NasdaqGS: AUTL)
Health Care · Biotechnology · GB
$1.77
-2.21% today · +21.5% 1Y
Autolus Therapeutics plc (NasdaqGS: AUTL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $481.75M and employs 752 people.
Over the last twelve months the share price has gained 21.5%, trading between 1.18 and 2.58.
Tweenvest scores Autolus Therapeutics plc across four factors: quality 29/100, value 64/100, growth 100/100. Its strongest factor is growth.
AUTL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $481.75M
- Revenue (TTM)
- $117.39M
- P/E
- —
- EPS
- -1.05
- Dividend yield
- —
- Beta (5Y)
- 2.14
- 52-week high
- $2.58
- 52-week low
- $1.18
- Avg volume (3M)
- —
- Shares outstanding
- 266.16M
- Employees
- 752
- Next earnings
- —
About Autolus Therapeutics plc
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
- ISIN
- US05280R1005
- Founded
- 2014
- Listed since
- Jun 22, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Guanhao Biotech Co.,Ltd.SZSE: 300238 | $489.37M | CN¥11.95 | -0.33% |
| Bright Minds Biosciences Inc.CNSX: DRUG | $488.45M | CA$73.52 | +4.15% |
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $486.06M | NT$216.00 | -5.26% |
| Qyuns Therapeutics Co., Ltd.SEHK: 2509 | $483.91M | HK$17.00 | +1.37% |
| Blau Farmacêutica S.A.BOVESPA: BLAU3 | $477.46M | R$10.82 | +5.87% |
| Eupraxia Pharmaceuticals Inc.TSX: EPRX | $477.13M | CA$10.73 | +3.97% |
| Shanghai Kehua Bio-Engineering Co.,LtdSZSE: 002022 | $472.33M | CN¥6.12 | +9.09% |
| Laekna, Inc.SEHK: 2105 | $472.14M | HK$8.75 | +26.81% |
Figures last refreshed Oct 4, 2026.